Prurigo Nodularis Therapeutics Market, by Product Type (Corticosteroids, Capsaicin Cream, Antihistamines, Anticonvulsants, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America,

Prurigo Nodularis Therapeutics Market, by Product Type (Corticosteroids, Capsaicin Cream, Antihistamines, Anticonvulsants, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Prurigo Nodularis is skin disease that causes hard and itchy lumps on skin, which usually appears on the arms or legs. Prurigo nodularis is a rare disease and currently, the treatment of the disease is still in research and development process. Treatments may include topical, oral, and intralesional corticosteroids; phototherapy; antihistamines; anxiolytics; opiate receptor antagonists; and thalidomide.
Market Dynamics
Key players are focusing on product approvals to strengthen their position in the global Prurigo nodularis therapeutics market. For instance, in October 2021, Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to its Vixarelimab drug for the treatment of pruritus associated with prurigo nodularis.
Key features of the study:
This report provides in-depth analysis of the global prurigo nodularis therapeutics market, provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global prurigo nodularis therapeutics market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
Key companies covered as a part of this study include Bayer AG, GlaxoSmithKline Plc., Johnson & Johnson Services, Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, Novartis AG, Celgene Corporation, VYNE Therapeutics Inc., Trevi Therapeutics Inc., Galderma SA, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Merck & Co. Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global Prurigo nodularis therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global prurigo nodularis therapeutics market.
Detailed Segmentation:
Global Prurigo Nodularis Therapeutics Market, By Product Type:
Corticosteroids
Capsaicin Cream
Antihistamines
Anticonvulsants
Others
Global Prurigo Nodularis Therapeutics Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Prurigo Nodularis Therapeutics Market, By Region:
North America
By Product Type
Corticosteroids
Capsaicin Cream
Antihistamines
Anticonvulsants
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
U.S.
Canada
Latin America
By Product Type
Corticosteroids
Capsaicin Cream
Antihistamines
Anticonvulsants
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Product Type
Corticosteroids
Capsaicin Cream
Antihistamines
Anticonvulsants
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Product Type
Corticosteroids
Capsaicin Cream
Antihistamines
Anticonvulsants
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Product Type
Corticosteroids
Capsaicin Cream
Antihistamines
Anticonvulsants
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
GCC
Israel
Rest of Middle East
Africa
By Product Type
Corticosteroids
Capsaicin Cream
Antihistamines
Anticonvulsants
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
South Africa
Central Africa
North Africa
Company Profiles
Bayer AG *
Company Overview
Product Portfolio
Financial Overview
Key Highlights
Market Strategies
GlaxoSmithKline Plc.
Johnson & Johnson Services, Inc.
Sanofi SA
Takeda Pharmaceutical Company Limited
Novartis AG
Celgene Corporation
VYNE Therapeutics Inc.
Trevi Therapeutics Inc.
Galderma SA
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
Merck & Co. Inc.
“*” marked represents similar segmentation in other categories in the respective section.